This article appears in the the BreastCancerUpdate Journal Vol 5. The article is edited by Mark D Pegram MD
Associate Professor of Medicine David Geffen School of Medicine at UCLA Director Women’s Cancer Program UCLA/Jonsson Comprehensive Cancer Center. Dr. Pegram covers many topics relevant to HER-2 positive breast cancer treatment including:

Early Phase I experience with trastuzumab/cisplatin in metastatic disease

Phase III randomized trial of trastuzumab/paclitaxel with or without carboplatin

Trastuzumab/platinum/taxane regimens

First-line therapy for patients with HER2-positive metastatic disease

BCIRG-006 adjuvant trastuzumab trial

Adjuvant trastuzumab in the nonprotocol setting

Influence of trastuzumab therapy on tumor HER2 status

Trials combining trastuzumab with hormonal therapy

Fulvestrant in clinical practice

Potential synergy between fulvestrant and trastuzumab

Trials combining trastuzumab with biologic agents (i.e. Erlotinib and Bevacizumab)

Treatment options for patients with ER-negative HER2- negative metastatic disease

Transition from hormonal therapy to chemotherapy

Phase III trial comparing capecitabine with or without bevacizumab

ECOG-E-2100: Phase III trial comparing paclitaxel with or without bevacizumab

Use of adjuvant dose-dense chemotherapy schedules

As you know Dr. Dennis Slamon (father of Herceptin/trastuzumab) is based at UCLA. I find the articles written or edited by the doctors at UCLA insightful.

Of course all treatment options should be discussed fully with your doctor.